Your browser doesn't support javascript.
loading
The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes.
Lin, Peipei; Ren, Yanling; Yan, Xiaomei; Luo, Yingwan; Zhang, Hua; Kesarwani, Meenu; Bu, Jiachen; Zhan, Di; Zhou, Yile; Tang, Yuting; Zhu, Shuanghong; Xu, Weilai; Zhou, Xinping; Mei, Chen; Ma, Liya; Ye, Li; Hu, Chao; Azam, Mohammad; Ding, Wei; Jin, Jie; Huang, Gang; Tong, Hongyan.
Afiliação
  • Lin P; Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Ren Y; Institute of Hematology, Zhejiang University, Hangzhou, China.
  • Yan X; Myelodysplastic Syndromes Diagnosis and Therapy Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Luo Y; Divisions of Pathology and Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, OH, USA.
  • Zhang H; Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Kesarwani M; Institute of Hematology, Zhejiang University, Hangzhou, China.
  • Bu J; Myelodysplastic Syndromes Diagnosis and Therapy Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Zhan D; Divisions of Pathology and Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, OH, USA.
  • Zhou Y; Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Tang Y; Institute of Hematology, Zhejiang University, Hangzhou, China.
  • Zhu S; Myelodysplastic Syndromes Diagnosis and Therapy Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Xu W; Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Zhou X; Institute of Hematology, Zhejiang University, Hangzhou, China.
  • Mei C; Myelodysplastic Syndromes Diagnosis and Therapy Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Ma L; Divisions of Pathology and Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, OH, USA.
  • Ye L; Divisions of Pathology and Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, OH, USA.
  • Hu C; Divisions of Pathology and Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, OH, USA.
  • Azam M; Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Ding W; Institute of Hematology, Zhejiang University, Hangzhou, China.
  • Jin J; Divisions of Pathology and Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, OH, USA.
  • Huang G; Divisions of Pathology and Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, OH, USA.
  • Tong H; Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Haematologica ; 104(3): 485-496, 2019 03.
Article em En | MEDLINE | ID: mdl-30262569
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Regulação da Expressão Gênica / Resistencia a Medicamentos Antineoplásicos / Citarabina / Fator 2 Relacionado a NF-E2 / Fosfatase 1 de Especificidade Dupla / Antimetabólitos Antineoplásicos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Haematologica Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Regulação da Expressão Gênica / Resistencia a Medicamentos Antineoplásicos / Citarabina / Fator 2 Relacionado a NF-E2 / Fosfatase 1 de Especificidade Dupla / Antimetabólitos Antineoplásicos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Haematologica Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China